Sertraline

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sertraline

Sertraline is a synthetic compound administered orally and classified as a Selective Serotonin Reuptake Inhibitor (SSRI), which is a psychotropic agent used for the modulation of mood.

Property Description
Active ingredient Sertraline Hydrochloride
Form Tablet, Oral concentrate, Capsule
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common purpose Support for mood and emotional balance
Origin Synthetic, Second-generation antidepressant

What Type of Medicine is Sertraline?

Sertraline is a second-generation antidepressant that functions as an SSRI by acting on chemical messengers in the brain. Its classification is widely recognized in clinical practice as one of the most frequently prescribed psychoactive medications globally. The primary pharmacological action of Sertraline is the selective inhibition of serotonin reuptake from the synaptic cleft, distinguishing it from older compounds like tricyclics. As an INN (International Nonproprietary Name), Sertraline is the chemical name used worldwide, while it is marketed under numerous popular brand names, all sharing the same Sertraline Hydrochloride formulation.


The Chemical Composition and Presentation of Sertraline

The medication contains Sertraline Hydrochloride as its active ingredient. It is designed for oral administration and is available in multiple dosage forms, including the solid tablet and the liquid oral concentrate solution. For patients who may have difficulty swallowing tablets, the concentrate provides an alternative for delivery of the active substance. The formulation is a single active ingredient product, which is a key characteristic of its specific mode of action.

What side effects are possible with Sertraline?

Possible side effects and safety information

The safety profile of Sertraline, a Selective Serotonin Reuptake Inhibitor (SSRI), is formally documented according to regulatory standards concerning the frequency and system affected by adverse reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on their documented rate of occurrence in clinical use:

  • Very Common (occurring in ge 1 in 10 users): Nausea, Diarrhea/Loose stools, Insomnia, Headache, and Ejaculation failure (in men).
  • Common (occurring in ge 1 in 100 users): Dizziness, Somnolence, Tremor, Decreased appetite, Dry mouth, Fatigue, and Hyperhidrosis (increased sweating).

Many of the most frequent effects are often cited as being transient upon continued use.

Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain rare but serious adverse reactions and key safety constraints, which are grouped by affected organ systems:

  • Psychiatric/Nervous System: The risk of Suicidal Thoughts and Behaviors is explicitly documented, particularly in children, adolescents, and young adults during the initial treatment phase and following dose adjustments. Serious reactions such as Serotonin Syndrome and Seizures/Convulsions are officially noted.
  • Metabolism/Vascular: Safety information notes the risk of Hyponatremia (low serum sodium), especially in Geriatric patients, and the potential for Hemorrhagic Events (e.g., gastrointestinal bleeding).

Population-Specific Safety Notes

The official label includes specific cautions for certain patient groups. Clearance of Sertraline is reduced in patients with Hepatic Impairment, potentially requiring dosage modification. For Pediatric Use, the medicine is only approved for specific indications, and there are documented risks concerning effects on growth rate and the increased incidence of suicidal thinking.

Overdose and Emergency Response

Sertraline Overdose and When to Seek Help

Official regulatory documentation describes Sertraline overdose as having a clinical profile characterized by central nervous system (CNS) and cardiovascular manifestations. Documented overdose presentations commonly include somnolence, agitation, confusion, fast heartbeat (tachycardia), tremor, nausea, vomiting, dizziness, fever, sweating, and loss of coordination.

Severe and Life-Threatening Outcomes

Overdose carries the potential for severe, life-threatening outcomes, including seizures and coma (loss of consciousness). Critical cardiovascular complications such as QTc prolongation and severe cardiac dysrhythmias have been reported. The specialized condition, Serotonin Syndrome, is also documented as a risk. Regulatory information notes that fatal outcomes are primarily associated with overdose in conjunction with co-ingestion of other drugs and/or alcohol.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. Because of the potential for severe escalation, emergency services (e.g., 911) must be contacted right away if the individual has collapsed, is having a seizure, has trouble breathing, or cannot be awakened. Regulatory guidance indicates there is no specific antidote for Sertraline. Management is focused strictly on supportive and symptomatic care, including establishing an airway, continuous vital sign monitoring, and considering activated charcoal. Emesis induction is not recommended in the official procedures.

Therapeutic Uses of Sertraline

What Sertraline Treats: Main Uses and Benefits

Sertraline is commonly used to help ease the overall symptom burden within its therapeutic domains. The medication is applied in conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and the recurrent manifestations of Obsessive-Compulsive Disorder (OCD). It is also relevant for providing supportive therapeutic benefit for the severe mood swings associated with Premenstrual Dysphoric Disorder (PMDD).


It is generally considered relevant when supportive symptom management is appropriate and is used for managing symptom clusters that may become intense or disruptive, such as persistent sadness, intrusive thoughts, and paralyzing fear. The support offered by Sertraline assists with maintaining functional stability, contributing to improved comfort during symptomatic periods. The medication is considered relevant for managing symptoms in both children and older adults.


Quick Fact: Relief for Anxiety and Intrusive Thoughts
Sertraline is used to help manage the intensity of recurrent obsessions, compulsions, and sudden, unexpected panic attacks.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sertraline?

The population eligibility for Sertraline is defined by strict regulatory criteria, classifying individuals as either contraindicated, conditionally eligible, or subject to specific age limitations.

Absolute Contraindications

Sertraline is contraindicated in patients with known hypersensitivity to the medicine or its excipients. It must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, and a mandatory 14-day washout period is required when switching between these agents. Concomitant use with pimozide is also prohibited.

Age-Specific Eligibility

Age Group Eligibility Status
Adults (18+) Eligible for all approved therapeutic uses.
Pediatric (6–17) Eligibility is restricted to the treatment of Obsessive-Compulsive Disorder (OCD) only.
Children (< 6) Safety and effectiveness are not established.

Condition-Based Restrictions

Use is advised with caution in patients with a history of mania or hypomania and those with seizure disorders; use should be avoided in cases of unstable epilepsy. Patients with hepatic impairment are eligible only under a cautionary condition, requiring a lower or less frequent dose in mild cases. No dosage adjustment is reported as necessary for renal impairment. Third-trimester use during pregnancy is associated with regulatory warnings regarding neonatal risks.

What should I know about interactions with other medicines?

The official interaction profile of Sertraline outlines several constraints related to co-administration. Contraindicated combinations include Monoamine Oxidase Inhibitors (MAOIs), such as the antibiotic linezolid, due to the severe, documented risk of Serotonin Syndrome. A mandatory 14-day washout period is required when switching between Sertraline and an MAOI in either direction. The antipsychotic agent Pimozide is also contraindicated based on the potential for increased Pimozide plasma levels and associated cardiac risk. The oral concentrate solution is specifically contraindicated with Disulfiram because of the concentrate’s alcohol content.

Sertraline is classified as an inhibitor of the CYP2D6 isoenzyme. This pharmacokinetic interaction can lead to increased plasma concentrations of co-administered drugs primarily metabolized by CYP2D6, such as certain tricyclic antidepressants. This interaction requires monitoring and potential dosage modification for the co-administered drug.

Pharmacodynamic interactions include an increased risk of bleeding when Sertraline is combined with other antiplatelet agents (like NSAIDs or aspirin) or anticoagulants (like warfarin). Co-administration with other serotonergic agents (e.g., Triptans) increases the collective risk of Serotonin Syndrome. The regulatory label advises against the concomitant use of alcohol and St. John's Wort. Furthermore, for the tablet formulation, co-administration with food is documented to increase the peak plasma concentration (Cmax). In the presence of hepatic impairment, a patient’s overall exposure to Sertraline and its active metabolite is documented to increase significantly.

Mechanism of Action

How Sertraline Works

Sertraline's primary function is as a selective inhibitor of the serotonin transporter (SERT). SERT is a transmembrane protein responsible for the reuptake of the neurotransmitter serotonin (5 -HT) from the synaptic cleft back into the presynaptic neuron.

By binding to SERT, sertraline blocks this reuptake process. This interaction constitutes the initial biological target and the resulting mechanistic cascade is a heightened concentration of 5 -HT within the synaptic cleft. This increased concentration modulates the activity of various post-synaptic 5 -HT receptors, which translates into a pathway modulation of the overall serotonergic system.

Sertraline exhibits minimal affinity for other major monoamine transporters, specifically the norepinephrine transporter (NET) and the dopamine transporter (DAT). This relative selectivity defines the drug's action profile at a system-level physiological consequence, primarily focusing on the serotonergic pathways.

Dosage and Administration Information

Administration Principles and Dosing Schedules

Sertraline is for oral administration and is taken once daily (qDay) for its established uses. The tablets may be taken with or without food. Specific starting doses are utilized depending on the condition being addressed. For Major Depressive Disorder and Obsessive-Compulsive Disorder, the starting dose is typically 50 mg/day. In contrast, a lower initial dose of 25 mg/day is utilized for conditions like Panic Disorder, Post-Traumatic Stress Disorder, and Social Anxiety Disorder.


Dosage Adjustment and Maximum Limits

Condition Group Standard Starting Dose Maximum Recommended Dose
MDD, OCD 50 mg/day 200 mg/day
PD, PTSD, SAD 25 mg/day 200 mg/day

Dosage adjustments, or titration, occur gradually, with changes made no more frequently than once per week. The maximum daily dose for most indications is 200 mg. Long-term use is established for preventing the recurrence of symptoms, and discontinuation requires a gradual reduction (tapering) in dosage.


Form-Specific and Population Instructions

For the oral concentrate solution, administration requires specific handling: it must be diluted immediately before use with only specific liquids, such as water or citrus sodas. Use in pediatric patients is restricted to Obsessive-Compulsive Disorder (OCD), with an initial dose of 25 mg/day for children aged 6–12 years. Standard protocols also include a 50% reduction in the initial and maximum dosage for patients with mild hepatic impairment.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clinical research on sertraline, a selective serotonin reuptake inhibitor (SSRI), continues to focus on refining its therapeutic profile across its established indications, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, and Social Anxiety Disorder.


Time to Effect and Symptom Response

A recent analysis of a large randomized controlled trial (RCT) in patients with depressive symptoms explored the onset of response at a granular symptom level. Initial findings suggested that sertraline was associated with a greater reduction in anxiety symptoms and emotional symptoms of depression within the first two to six weeks, compared to an effect on the overall depressive score. Specific emotional symptoms, such as low mood, self-loathing, and suicidal thoughts, were reported to show improvement earlier than previously understood, sometimes within two weeks.

These studies suggest that the overall perception of effectiveness may be influenced by certain somatic side effects, such as changes in sleep or libido, which may emerge early in treatment. The research emphasizes that the full range of potential benefits may not be observed until 12 weeks of treatment or later.


Focus on Specific Populations

Ongoing clinical research is investigating the effect of sertraline in various populations and for conditions outside of its primary indications, such as:

  • Treatment-Resistant OCD: Exploration of combination therapies, such as the addition of other medications to sertraline, for patients who do not respond adequately to initial SSRI monotherapy.
  • New Applications: Trials are in progress to evaluate the potential role of sertraline in managing depression and anxiety symptoms within specific medical contexts, such as heart failure and following a traumatic brain injury (TBI).
  • Individualized Response: Studies are working to identify biological markers (biomarkers) that may predict an individual patient's response to sertraline treatment, aiming for more precise prescribing decisions in the future.

Key Studies & References

  1. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial

Frequently Asked Questions (FAQ)

Common questions about Sertraline (FAQ)


Q: How long does it typically take to feel the main effect of Sertraline?

A: Regulatory documents indicate that clinical trials observed improvement in some physical symptoms starting within the first one to two weeks of treatment. However, the full range of potential benefits, including a noticeable change in emotional symptoms, often takes longer, sometimes requiring 8 to 12 weeks of consistent use or more.


Q: Is a loss of interest in sexual activity a common side effect of Sertraline?

A: Sexual dysfunction is a known risk described in official documents. This covers a range of issues including reduced sexual drive (libido), difficulty with arousal, and challenges with reaching orgasm. Ejaculation failure in men is specifically classified as a very common side effect.


Q: Can taking Sertraline cause changes in body weight?

A: Clinical data describes changes in body weight associated with Sertraline. Decreased appetite has been reported, and the use of the medicine is also associated with reports of weight gain. These changes are noted across the patient population.


Q: Do initial side effects like nausea or anxiety usually decrease over time?

A: Regulatory documents describe many frequent undesirable effects, including nausea, as being transient in nature, meaning they were observed to decrease with continued treatment. The risk of anxiety and agitation is also noted, especially when a person first starts taking the medicine or changes the dose.


Q: Can Sertraline affect sleep patterns, causing insomnia or vivid dreams?

A: Insomnia (difficulty sleeping) is classified as a very common adverse reaction in official safety information. Vivid dreams are also listed in regulatory documents as a reported adverse reaction associated with the drug's use.


Q: Is it possible for Sertraline to worsen symptoms of bipolar disorder or cause a manic episode?

A: Regulatory safety information warns that Sertraline may lead to the activation of mania or hypomania (a less severe form of mania). For patients with a history of bipolar disorder, regulatory information notes the need for monitoring for the emergence of a manic episode.


Q: What kind of monitoring is recommended while taking Sertraline for an extended period?

A: Regulatory documents describe the need to monitor for clinical worsening and the emergence of new symptoms, particularly when first starting the medicine or following dose adjustments. Monitoring for specific issues like low serum sodium (hyponatremia) and liver function is also described as appropriate for certain individuals.


Q: Is the tiredness or fatigue experienced with Sertraline generally temporary?

A: Fatigue and somnolence (drowsiness) are described as common adverse reactions. Official sources note that many frequent effects are often transient and were observed to improve as treatment continued.


Q: What are some common misconceptions about how fast Sertraline starts to work?

A: A common misconception is that the drug produces an immediate noticeable effect. While initial improvement in physical symptoms may start in one to two weeks, it typically takes several weeks, often 8 or more, to achieve the full beneficial effect on emotional well-being.


Q: Can Sertraline affect a woman's menstrual cycle or period regularity?

A: Sertraline is approved for the treatment of Premenstrual Dysphoric Disorder (PMDD), a condition related to the menstrual cycle. In addition to its PMDD approval, post-marketing data has noted reports of changes in the menstrual cycle, such as delayed periods, associated with SSRIs like Sertraline.


Q: Does Sertraline have a potential for being misused?

A: In clinical studies, the drug did not exhibit characteristics suggestive of misuse potential. However, regulatory documents state that abrupt stopping may produce discontinuation symptoms. Regulatory documents note that healthcare providers should monitor patients for signs suggestive of misuse.


Q: Can grapefruit or grapefruit juice affect how Sertraline works?

A: Official patient information notes that grapefruit or grapefruit juice may increase the amount of Sertraline in the body. This interaction can increase the potential for side effects.


Q: What is the purpose of the liquid concentrate form of Sertraline?

A: The oral concentrate solution is provided as an alternative dosage form. Its main purpose is to allow individuals who may have difficulty swallowing tablets to take the medicine.


Q: Is it normal to feel more anxious or restless when first starting Sertraline?

A: Increased anxiety and agitation are effects noted in regulatory safety information, particularly when beginning treatment or adjusting the dose. Restlessness or anxiety, especially if severe, are also symptoms that may be associated with more serious reactions such as Serotonin Syndrome or activation of hypomania.


Q: What is the possibility of experiencing an allergic reaction to Sertraline?

A: Sertraline is contraindicated (should not be used) if a person has a known hypersensitivity (an allergic reaction) to the active ingredient or its inactive components. Serious reactions such as rash, hives, or swelling are described as potentially occurring and should be immediately reported to a healthcare provider.


Q: Does Sertraline affect the ability to drive or operate machinery?

A: The medicine can cause dizziness or somnolence (drowsiness) as common side effects. Due to the potential for these effects, caution is noted regarding performing tasks that require mental alertness, such as driving or operating heavy machinery.


Q: Is it necessary to take Sertraline at the exact same time every day?

A: The medicine is prescribed for once-daily administration. Since the medicine is prescribed for once-daily administration, maintaining a consistent routine for daily intake helps ensure stable levels of the medication in the body, as per official guidance.


Q: What happens in the body when a person stops taking Sertraline suddenly?

A: Abrupt discontinuation is described as potentially leading to discontinuation syndrome (sometimes called withdrawal symptoms). These symptoms can include dizziness, sensory disturbances (like tingling), agitation, anxiety, and sleep disturbances.


Q: Are there research studies comparing Sertraline's safety profile to placebo?

A: Regulatory approvals for Sertraline are based on controlled clinical trials. These trials, which compare the drug's effects and safety to an inactive placebo, are the source of the official documented adverse reaction frequencies.


Q: Does taking Sertraline increase the risk of bleeding or bruising?

A: The official label notes an increased risk of bleeding or bruising. This is particularly the case for the skin or gastrointestinal tract, and the risk can occur when Sertraline is taken alone or with other medications that affect bleeding.


Q: Do the tablets contain any common allergens that users should be aware of?

A: Sertraline is contraindicated in patients with a known hypersensitivity to the drug or its excipients (inactive ingredients). The complete list of inactive ingredients for a specific product is detailed in the official prescribing information for users to check.


Q: What are the signs of a very low sodium level (hyponatremia) that can be associated with Sertraline use?

A: Hyponatremia (low sodium in the blood) is a noted risk. Signs of this condition can include headache, weakness, unsteadiness, confusion, or memory problems. Serious cases can lead to seizures and other severe neurological and medical issues.


Q: Can taking Sertraline be related to jaw clenching or teeth grinding (bruxism)?

A: Bruxism (jaw clenching or teeth grinding) is listed in regulatory documents as an adverse reaction that has been reported during the use of Sertraline, typically noted in post-marketing experience.


Q: How does Sertraline's use relate to anxiety disorders like Panic Disorder or Social Anxiety Disorder?

A: Sertraline is officially indicated and approved for the treatment of multiple anxiety-related conditions, including Panic Disorder, Social Anxiety Disorder, and Post-Traumatic Stress Disorder. Its regulatory approval confirms its established use in these areas.


Q: What non-drug components are used to dilute the Sertraline oral concentrate?

A: Official dosing instructions specify that the liquid concentrate must be diluted immediately before use with only specific liquids. These approved non-drug components include water, lemon/lime soda, orange juice, or ginger ale.


Q: Is any difference in effect between the brand name and the generic form of Sertraline?

A: According to regulatory standards, the generic form of Sertraline contains the identical active ingredient in the same strength. To receive approval, it must be bioequivalent to the brand-name product, meaning it works the same way and produces the same therapeutic effect in the body.

How should Sertraline be stored and disposed of?

How to Store and Dispose of Sertraline

Sertraline must be stored at controlled room temperature, specifically between 20^circ to 25 C (68^circ to 77 F), with excursions permitted up to 30 C. The medication must be kept in its original, tightly closed container, protected from excessive heat and moisture. The oral concentrate solution must be used within 28 days after the bottle is first opened. To prevent accidental ingestion, sertraline must always be stored out of the sight and reach of children.

Disposal should follow official guidelines. Unused or expired medication should be taken to an authorized drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, seal it in a plastic bag, and dispose of it in the household trash. Do not flush sertraline down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sertraline found in:

A-Z Index: